Products

What will AGI do for Acoxatrine?

This classification denotes a vasodilating agent with the molecular formula C23H28N2O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7IGS0KX75Q, chemically known as 2-(4-(acetamidomethyl)-4-phenyl-1-piperidyl)methyl-1,4-benzodioxane but generally known as acoxatrine, which bears US NIH Compound Identifier 68938. European Medicines Agency schedules Acoxatrine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05247MIG. The term ACOXATRINE is an International Non-Proprietary Name. ACOXATRINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Most nations schedule acoxatrine under HS 29349990 and SITC 51579. As of Q4 2014, ACOXATRINE remains the US FDA Preferred Term for this commodity. Acoxatrine bears US NLM identifiers UMLS ID C2699761 and NCI Concept Code C74418. SMILES: O1C(CN2CCC(CC2)(CNC(=O)C)c2ccccc2)COc2c1cccc2.

How AGI delivers it

Four ways AGI delivers for Acoxatrine

  • Headless SaaS for Agents

    Give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

    For Acoxatrine, give your tools an agent-consumable surface (API / MCP / SDK) so agents can do the work.

  • Services-as-Software

    Get the professional outcome delivered as software, priced on results, not headcount.

    For Acoxatrine, get the professional outcome delivered as software, priced on results, not headcount.

Value flow

How Acoxatrine connects

measured by

  • Active Yieldmodel
  • Chemical Puritymodel